骨髓增殖性肿瘤的组织学评估
Histological evaluation of myeloproliferative neoplasms.
作者信息
Fujiwara Hideyo
出版信息
J Clin Exp Hematop. 2018;58(2):45-50. doi: 10.3960/jslrt.18006.
Abstract
In 2017, the revised World Health Organization was published. Regarding myeloproliferative neoplasms, histological findings of bone marrow biopsy is becoming more important for diagnosis. This article highlights particularly the morphology of megakaryocytes and evaluation of myelofibrosis for pathological diagnosis, and immunohistochemistry which can detect somatic mutation.
摘要
2017年，世界卫生组织修订版发布。关于骨髓增殖性肿瘤，骨髓活检的组织学检查结果对诊断愈发重要。本文特别强调巨核细胞的形态学以及用于病理诊断的骨髓纤维化评估，还有能够检测体细胞突变的免疫组织化学。
相似文献
1
Histological evaluation of myeloproliferative neoplasms.骨髓增殖性肿瘤的组织学评估
J Clin Exp Hematop. 2018;58(2):45-50. doi: 10.3960/jslrt.18006.
2
[Recent advances in bone marrow pathology for myeloproliferative neoplasms diagnosis].[骨髓病理学在骨髓增殖性肿瘤诊断中的最新进展]
Rinsho Ketsueki. 2024;65(8):778-783. doi: 10.11406/rinketsu.65.778.
3
[Histological diagnosis of Ph-negative myeloproliferative neoplasia. An overview].[Ph阴性骨髓增殖性肿瘤的组织学诊断。综述]
Cesk Patol. 2011 Jul;47(3):84-93.
4
[Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].[骨髓活检在骨髓增殖性肿瘤诊断中的应用]
Gac Med Mex. 2016 May-Jun;152(3):407-18.
5
Acute megakaryocytic myelofibrosis. Case report of an unusual myeloproliferative syndrome.急性巨核细胞性骨髓纤维化。一例罕见骨髓增殖性综合征的病例报告。
Am J Clin Pathol. 1974 Jul;62(1):52-9. doi: 10.1093/ajcp/62.1.52.
6
Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.组织病理学在急性髓系白血病、骨髓增生异常综合征及骨髓增生异常/骨髓增殖性疾病的诊断与分类中的应用
Pathobiology. 2007;74(2):97-114. doi: 10.1159/000101709.
7
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.真性红细胞增多症、原发性血小板增多症以及原发性骨髓纤维化伴或不伴JAK2 V617F突变时的巨核细胞形态及临床参数
Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA.
8
Elliptic Fourier analysis of megakaryocyte nuclei in chronic myeloproliferative disorders.慢性骨髓增殖性疾病中巨核细胞核的椭圆傅里叶分析
Anal Quant Cytol Histol. 1992 Oct;14(5):391-7.
9
Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia.原发性骨髓纤维化（PMF）中的血栓反应蛋白-1（TSP-1）——一种主要用于区分 PMF 和特发性血小板增多症的巨核细胞来源的生物标志物。
Ann Hematol. 2011 Jan;90(1):33-40. doi: 10.1007/s00277-010-1024-z. Epub 2010 Jul 13.
10
[Acute myelofibrosis: apropos of a case with immunocytochemical and ultrastructural studies].[急性骨髓纤维化：关于一例免疫细胞化学和超微结构研究的病例]
Med Clin (Barc). 1989 Jan 28;92(3):102-3.
引用本文的文献
1
Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology.经典骨髓增殖性肿瘤的细胞形态学诊断：分子生物学时代
Cells. 2023 Mar 20;12(6):946. doi: 10.3390/cells12060946.
本文引用的文献
1
Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data.原发性血小板增多症与纤维化前期/早期原发性骨髓纤维化：通过实验室和临床数据进行鉴别
Blood Cancer J. 2017 Dec 13;7(12):643. doi: 10.1038/s41408-017-0006-y.
2
CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms.CAL2免疫组织化学染色可准确识别骨髓增殖性肿瘤中的CALR突变。
Am J Clin Pathol. 2016 Oct;146(4):431-8. doi: 10.1093/ajcp/aqw135.
3
Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms.突变特异性免疫组化对骨髓增殖性肿瘤中钙网蛋白突变的存在具有高度特异性。
Pathology. 2016 Jun;48(4):319-24. doi: 10.1016/j.pathol.2016.03.002. Epub 2016 Apr 22.
4
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
5
Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis.JAK2选择性抑制剂fedratinib治疗对骨髓纤维化患者骨髓纤维化的影响。
J Transl Med. 2015 Sep 10;13:294. doi: 10.1186/s12967-015-0644-4.
6
A new monoclonal antibody (CAL2) detects CALRETICULIN mutations in formalin-fixed and paraffin-embedded bone marrow biopsies.一种新型单克隆抗体（CAL2）可检测福尔马林固定石蜡包埋骨髓活检组织中的钙网蛋白突变。
Leukemia. 2016 Jan;30(1):131-5. doi: 10.1038/leu.2015.192. Epub 2015 Jul 23.
7
TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.TP53过表达是伴有纤维化的初发骨髓增生异常综合征的一个独立不良预后因素。
Br J Haematol. 2015 Oct;171(1):91-9. doi: 10.1111/bjh.13529. Epub 2015 Jun 30.
8
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.真性红细胞增多症、原发性血小板增多症以及原发性骨髓纤维化伴或不伴JAK2 V617F突变时的巨核细胞形态及临床参数
Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA.
9
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.高危骨髓增生异常综合征和继发性急性髓系白血病中对阿扎胞苷的反应与p53表达无关。
Haematologica. 2014 Oct;99(10):e179-81. doi: 10.3324/haematol.2014.104760. Epub 2014 Jun 27.
10
Novel myelofibrosis treatment strategies: potential partners for combination therapies.新型骨髓纤维化治疗策略：联合治疗的潜在伙伴。
Leukemia. 2014 Nov;28(11):2139-47. doi: 10.1038/leu.2014.176. Epub 2014 Jun 3.
Zotero 插件